Previous clinical trials indicate that 10%–25% of patients received genomically matched therapy after comprehensive genomic profiling (CGP) tests. However, the clinical utility of CGP tests has not been assessed in clinical practice. We assessed the clinical utility of CGP tests for advanced or metastatic solid tumor and determined the proportion of patients receiving genomically matched therapy among those with common and non-common cancers. From August 2019 to July 2020, a total of 418 patients had undergone CGP tests, and the results were discussed through the molecular tumor board at our site. The median age of patients was 57 (range: 3–86) years. Colorectal cancer was the most common, with 47 (11%) patients. Actionable genomic alterations (median 3, range: 1–17) were identified in 368 (88.0%) of 418 patients. Druggable genomic alterations were determined in 196 (46.9%) of 418 patients through the molecular tumor board. Genomically matched therapy was administered as the subsequent line of therapy in 51 (12.2%) patients, which is comparable to the proportion we previously reported in a clinical trial (13.4%) (p = 0.6919). The proportion of patients receiving genomically matched therapy was significantly higher among those with common cancers (16.2%) than non-common cancers (9.4%) (p = 0.0365). Genomically matched therapy after the CGP tests was administered to 12.2% of patients, which is similar to the proportion reported in the previous clinical trials. The clinical utility of CGP tests in patients with common cancers greatly exceeded that in patients with non-common cancers.

中文翻译：

---

晚期或转移性实体瘤综合基因组分析测试在临床实践中的临床应用

先前的临床试验表明，10%–25% 的患者在综合基因组分析 (CGP) 测试后接受了基因组匹配的治疗。然而，CGP 测试的临床效用尚未在临床实践中得到评估。我们评估了 CGP 检测对晚期或转移性实体瘤的临床效用，并确定了接受基因组匹配治疗的患者在常见和非常见癌症患者中的比例。从2019年8月到2020年7月，共有418名患者接受了CGP检测，结果通过我们中心的分子肿瘤委员会进行了讨论。患者的中位年龄为 57 岁（范围：3-86 岁）。结直肠癌最常见，有 47 名 (11%) 患者。在 418 名患者中的 368 名 (88.0%) 中发现了可操作的基因组改变（中位数 3，范围：1–17）。通过分子肿瘤委员会在 418 名患者中的 196 名 (46.9%) 中确定了药物基因组改变。51 名 (12.2%) 患者接受了基因组匹配治疗作为后续治疗，这与我们之前在临床试验中报告的比例 (13.4%) 相当（p  = 0.6919）。接受基因组匹配治疗的患者比例在普通癌症患者中 (16.2%) 显着高于非常见癌症患者 (9.4%) ( p  = 0.0365)。12.2% 的患者接受了 CGP 测试后的基因组匹配治疗，这与之前临床试验中报告的比例相似。CGP 检测在常见癌症患者中的临床效用大大超过非常见癌症患者。